LFG
CMPX icon

Larson Financial Group’s Compass Therapeutics CMPX Stock Holding History

Larson Financial Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204 Buy
93
+70
+304% +$207 ﹤0.01% 3599
2026
Q1 		$122 Buy
+23
New +$133 ﹤0.01% 3504

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Larson Financial Group's CMPX Position: Q2 2026 in Review

Larson Financial Group increased its Compass Therapeutics (CMPX) stake by 304% in Q2 2026, buying an estimated $207 and bringing the position to 93 shares worth $204. The position accounts for ﹤0.01% of the portfolio, ranked #3599.

Larson Financial Group first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Larson Financial Group held 93 shares of Compass Therapeutics worth $204 as of Q2 2026.
  • Larson Financial Group bought 70 Compass Therapeutics shares in Q2 2026, an estimated $207.
  • Compass Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3599 holding.
  • Larson Financial Group first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.